Stevanato Group

Stevanato Group appoints Ugo Gay as Chief Operations Officer

Retrieved on: 
Thursday, April 4, 2024
Medical Supplies, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Organization, DiaSorin, Growth, Stevanato Group, Information, Piombino Dese, Ugo, Investment, Multimedia, Development, Management

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
  • View the full release here: https://www.businesswire.com/news/home/20240404727049/en/
    Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire)
    The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain.
  • Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations.
  • “I am honored to help lead Stevanato Group's journey towards operational excellence, driving sustainable growth across our global footprint while fostering innovation," said Ugo Gay, Chief Operations Officer at Stevanato Group.

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

Retrieved on: 
Tuesday, March 26, 2024
Medical Supplies, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Citigroup, BofA Securities, Exercise, Offering, Form, Telephone, Stevanato Group, William Blair & Company, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, KeyBank, Varick Street, 2nd Floor

Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).

Key Points: 
  • Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
  • The total gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $379.7 million, or approximately $189.8 million from each of the Company Offering and the Selling Shareholder Offering.
  • Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
  • Morgan Stanley and William Blair served as lead book-running managers and as representatives of the underwriters for the Offering.

Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Citigroup, BofA Securities, Exercise, Offering, Form, Telephone, Stevanato Group, William Blair & Company, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, KeyBank, Varick Street, 2nd Floor

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
  • Stevanato Group is offering 6,350,000 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering 6,350,000 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
  • Stevanato Group and the Selling Shareholder have granted the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to 1,905,000 additional ordinary shares on the same terms and conditions.
  • Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.

Stevanato Group Announces Public Offering of Ordinary Shares

Retrieved on: 
Wednesday, March 20, 2024
Medical Supplies, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Form, Telephone, Stevanato Group, William Blair & Company, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, Varick Street, 2nd Floor

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.
  • Stevanato Group is offering $150,000,000 of its ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering $150,000,000 of its ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
  • Stevanato Group and the Selling Shareholder also intend to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase additional ordinary shares up to an amount equal to 15% of the aggregate number of ordinary shares offered in the Offering on the same terms and conditions.
  • Stevanato Group intends to use the net proceeds from the Company Offering for general corporate purposes, including to enable Stevanato Group to satisfy the requirements of its ongoing investment activities and working capital needs, and to ensure an appropriate level of operating and strategic flexibility.

Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Pharmaceutical, Health, Conference call, Biopharmaceutical, COVID-19, BDS, PIN, Investment, Growth, Syringe, Segment, Conference, Glass, Webcast, Stevanato Group, Public expenditure, EPS, Depreciation, DCS

Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue.

Key Points: 
  • Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue.
  • For fiscal year 2023, revenue increased 10% to €1,085.4 million, and high-value solutions represented 34% of total revenue.
  • Excluding revenue contributions from Covid-19, revenue grew approximately 24% in the fourth quarter of 2023, compared with the same period in 2022.
  • Revenue from high-value solutions increased to 34% of total revenue for fiscal year 2023, compared with 30% last year.

Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization

Retrieved on: 
Wednesday, January 24, 2024
Technology, Medical Devices, General Health, Professional Services, Infectious Diseases, Medical Supplies, Clinical Trials, FDA, Diabetes, Biotechnology, Health, Health Technology, Hardware, Radiology, Pharmaceutical, Finance, Oncology, Senior, Stevanato Group, Patient, TEC, Syringe, Glass, Multimedia, Kit, Safety, Drug development, F46, Growth, Fine chemical

The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies.

Key Points: 
  • The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies.
  • The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier.
  • EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.
  • Additionally, to better support customers, Stevanato Group has introduced a non-GMP laboratory filling and finishing service at its Technology Excellence Centers (TEC) in Boston, USA, and Piombino Dese, Italy.

Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing

Retrieved on: 
Thursday, November 16, 2023
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Syringe, Glass, Safety, NYSE, Stevanato Group, Multimedia, Combi, Quality control, Endeavor Business Media, Engineering, Pharma, Fine chemical

View the full release here: https://www.businesswire.com/news/home/20231116606597/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231116606597/en/
    Stevanato Group's Mavis™ Combi machine for visual inspection.
  • The Mavis™ Combi visual inspection line is a cutting-edge solution designed to provide advanced performance, flexibility, and speed to enhance visual inspection of primary packaging and the drugs within it.
  • The Mavis™ Combi is part of Stevanato Group's Mavis™ platform, which also includes equipment for visual inspection of syringes.
  • “It's a privilege to be acknowledged for the innovation behind the Mavis™ Combi visual inspection line,” said Paolo Superchi, Vice President of Engineering Operations at Stevanato Group.

OtterBox Launches Defender Series XT Division 2 for Use in Hazardous Locations

Retrieved on: 
Monday, November 13, 2023
IPhone 14, Agriculture, Safety, OtterBox, Dust, Stevanato Group, Smartphone, Mining, United, Division II, Gas, Communication, Aviation, IPhone, MagSafe, Risk management, Explosive

FORT COLLINS, Colo., Nov. 13, 2023 /PRNewswire/ -- OtterBox, the #1 most trusted smartphone case brand in the U.S., introduces its latest industrial focused solution: Defender Series XT Division 2 for iPhone 14. This ultra-rugged, device-integrated protective case is certified by UL Solutions and developed to safeguard tech in certain hazardous locations, helping to improve worksite safety and efficiency in harsh environments.

Key Points: 
  • FORT COLLINS, Colo., Nov. 13, 2023 /PRNewswire/ -- OtterBox, the #1 most trusted smartphone case brand in the U.S., introduces its latest industrial focused solution: Defender Series XT Division 2 for iPhone 14.
  • "Defender Series XT Division 2 advances our portfolio of device-integrated case solutions designed and third-party certified for use in challenging environments," said OtterBox Chief Commercial Officer Berkley Fuller.
  • "Appropriately protected mobile solutions enable the use of digital tools and technology which can increase safety, communication, convenience and efficiency for workers at industrial locations, and OtterBox is proud to offer Defender Series XT Division 2 to meet that need."
  • Defender Series XT Division 2 for iPhone 14 joins the OtterBox portfolio of industrial-grade solutions, including Hardline Series.

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, Pharmaceutical, Type, Elastomer, FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Container, SCHOTT, Dätwyler, West Pharmaceutical Services, Glass, BARDA, Development, Growth, COVID-19, RTU, Duran (glass), EMA, Porta Nuova (Milan), Safety, Material, EZ, Investment, Syringe, Value proposition, Patient safety, Sterilization, Medical device, Fine chemical, Borosilicate glass, Stevanato Group

This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.

Key Points: 
  • This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.
  • It's essential to highlight that the growing demand for secure drug delivery systems has fueled the expansion of the global pharmaceutical packaging market.
  • The integration of ready-to-use (RTU) packaging containers in the pharmaceutical sector enables expedited product launches through an optimized value chain.
  • The current landscape of pre-sterilized / ready to use pharmaceutical primary packaging features close to 95 RTU containers and 85 RTU closures.

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size to Expand Lucratively and Reach $14.23 Bn to 2031 - Explained Details | Updated InsightAce Study

Retrieved on: 
Wednesday, October 25, 2023
FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Government, ATMP, SCHOTT, Dätwyler, West Pharmaceutical Services, BARDA, Development, Growth, Schott, COVID-19, RTU, Duran (glass), EMA, Nuova Cometra, SGD, Medication, Investment, Patient safety, Medical device, Beauty salon, Stevanato Group

The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.

Key Points: 
  • The main factors responsible for driving the Pre-Sterilized/Ready to Use Pharmaceutical packaging market are increasing preference towards patient safety and rising importance for sterility and integrity of pharmaceutical products.
  • In addition, strict regulatory guidelines set by regulatory agencies such as the FDA and EMA play an essential role in booming the demand for pre-sterilized pharmaceutical packaging.
  • The addition of RTU (ready-to-use) packaging into the pharmaceutical industry ensures that the product is quickly available through the optimized supply chain.
  • Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Container
    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Closure